Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Rhea-AI Summary

Sensei Biotherapeutics (Nasdaq: SNSE) announced it will present new preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference in New York from September 28 to October 1, 2022. The poster presentation is scheduled for September 30, highlighting SNS-101's favorable pharmacokinetic properties and its potential to enhance anti-PD-1 responses. This aligns with Sensei's mission of developing next-generation cancer therapeutics.

Positive

• Presentation of new preclinical data on SNS-101 indicates favorable pharmacokinetic and cytokine release characteristics.
• SNS-101 may enhance anti-PD-1 responsiveness, presenting a potential advancement in cancer immunotherapy.

Negative

• None.

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – October 1, 2022 at the New York Hilton Midtown in New York, New York.

Presentation Details:

Presentation Type: Poster
Title: SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness
Date and Time: Friday, September 30, from 12:15 pm-2:15 pm ET.
Session: Poster Session B

The full abstract will be available online as a supplement to the AACR journal, Cancer Immunology Research. The poster will be made available on the Sensei Bio website following the presentation.

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Sensei’s product candidates and platforms, including SNS-101; the expected safety profile of Sensei’s product candidates, including SNS-101; and the potential benefits of SNS-101. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies, including the preclinical studies described in this press release, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2022 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

 

FAQ

What is the focus of Sensei Biotherapeutics?

Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer, particularly through immuno-oncology.

When will Sensei Biotherapeutics present data on SNS-101?

Sensei Biotherapeutics will present data on SNS-101 on September 30, 2022, at the CRI-ENCI-AACR Conference.

What is SNS-101 targeting?

SNS-101 is a monoclonal antibody targeting the immune checkpoint VISTA in the tumor microenvironment.

What are the implications of SNS-101's pharmacokinetic properties?

The favorable pharmacokinetic properties of SNS-101 suggest it may have potential therapeutic benefits in enhancing anti-tumor responses.

Where can I find the full abstract of the SNS-101 presentation?

The full abstract will be published as a supplement to the AACR journal, Cancer Immunology Research, and will also be available on Sensei Biotherapeutics' website.